Eastover Investment Advisors’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-76,628
Closed -$6.05M 47
2023
Q4
$6.05M Buy
76,628
+1,008
+1% +$71.7K 3.2% 15
2023
Q3
$5.28M Buy
75,620
+1,237
+2% +$87.6K 3.17% 18
2023
Q2
$5.14M Buy
74,383
+12,219
+20% +$869K 2.74% 19
2023
Q1
$4.62M Buy
62,164
+1,431
+2% +$120K 2.58% 25
2022
Q4
$5.66M Buy
60,733
+621
+1% +$59.9K 3.24% 17
2022
Q3
$5.3M Buy
60,112
+649
+1% +$64.2K 3.31% 11
2022
Q2
$5.51M Buy
59,463
+1,640
+3% +$160K 3.36% 14
2022
Q1
$5.85M Buy
57,823
+6,496
+13% +$682K 3.09% 15
2021
Q4
$5.29M Buy
51,327
+730
+1% +$67.5K 3.06% 14
2021
Q3
$4.29M Buy
50,597
+908
+2% +$76.1K 2.8% 21
2021
Q2
$4.15M Buy
49,689
+1,175
+2% +$96.2K 2.69% 21
2021
Q1
$3.65M Sell
48,514
-2,244
-4% -$163K 2.58% 24
2020
Q4
$3.47M Sell
50,758
-1,302
-3% -$84.7K 2.4% 24
2020
Q3
$3.04M Buy
52,060
+2,558
+5% +$159K 2.31% 27
2020
Q2
$3.22M Buy
49,502
+2,046
+4% +$129K 2.66% 23
2020
Q1
$2.82M Buy
+47,456
New +$3.17M 2.73% 20

Other funds holding CVS

Eastover Investment Advisors's CVS Position: Q1 2024 in Review

Eastover Investment Advisors sold out of CVS Health (CVS) in Q1 2024, closing a stake of 76,628 shares — an estimated $6.05M sold.

Eastover Investment Advisors first reported a position in CVS in Q1 2020 and held it in 16 quarters. The position peaked at $6.05M in Q4 2023. 2,176 funds tracked by Wall St. Rank hold CVS as of Q1 2024.

  • Eastover Investment Advisors reported no remaining CVS Health position as of Q1 2024 after selling out during the quarter.
  • Eastover Investment Advisors sold 76,628 CVS Health shares in Q1 2024, an estimated $6.05M.
  • Eastover Investment Advisors first reported a position in CVS Health in Q1 2020 and held it in 16 quarters.
  • Eastover Investment Advisors's CVS Health position peaked at $6.05M in Q4 2023.
  • 2,176 funds tracked by Wall St. Rank held CVS Health as of Q1 2024.

Based on Eastover Investment Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.